Quest Diagnostics (DGX) has been experiencing positive sentiment from Wall Street analysts, attracting significant attention from investors. The company's
stock holdings have been increased by renowned asset management giants like Vanguard Group Inc, Cibc World Market Inc, and others, indicating strengthening confidence in Quest's performance. Pleasing investors, Quest recently announced
dividend hike coupled with expanded buyback, while high ranking officials exercised their stock options. The company also looks to improve the lab testing experience through an industry-first collaboration with Epic. There's a positive projection for
future earnings based on strong, consistent
financial results and raised guidance. Quest has launched a novel
myeloma test and enhanced
dividends, further boosting its valuation. Institutional investors continue to invest in DGX amid market indicators of steady growth and high performance. Jefferies keeps a 'Buy' rating on the stock as the company continues its impressive streak on Fortune's World's Most Admired Companies list. Quest's partnership with Epic alongside its acquisition of clinical testing assets from Fresenius Medical, is expected to enhance its service portfolio.
Quest Diagnostics DGX News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 03:25:00 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor -7
